Tango Therapeutics Inc (TNGX)
7.89
+0.28
(+3.68%)
USD |
NASDAQ |
May 06, 16:00
7.89
0.00 (0.00%)
After-Hours: 20:00
Tango Therapeutics Cash from Operations (TTM): -117.98M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -117.98M |
September 30, 2023 | -118.78M |
June 30, 2023 | -107.26M |
March 31, 2023 | -114.32M |
December 31, 2022 | -109.08M |
Date | Value |
---|---|
September 30, 2022 | -97.72M |
June 30, 2022 | -99.60M |
March 31, 2022 | -75.58M |
December 31, 2021 | -59.53M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-118.78M
Minimum
Sep 2023
-59.53M
Maximum
Dec 2021
-99.98M
Average
-107.26M
Median
Jun 2023
Cash from Operations (TTM) Benchmarks
Aquestive Therapeutics Inc | -6.38M |
2seventy bio Inc | -166.86M |
NovaBay Pharmaceuticals Inc | -4.131M |
Palatin Technologies Inc | -26.54M |
iBio Inc | -18.89M |